Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives $56.36 Average PT from Analysts

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) have earned an average recommendation of “Moderate Buy” from the fifteen brokerages that are currently covering the company, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $56.36.

A number of equities analysts have commented on the stock. HC Wainwright boosted their target price on shares of Kymera Therapeutics from $54.00 to $60.00 and gave the stock a “buy” rating in a report on Friday, February 28th. Citigroup initiated coverage on shares of Kymera Therapeutics in a research note on Thursday, March 13th. They set a “buy” rating and a $52.00 price objective for the company. Leerink Partners restated an “outperform” rating and issued a $60.00 target price on shares of Kymera Therapeutics in a research note on Friday, December 27th. Finally, Stephens reaffirmed an “overweight” rating and set a $60.00 price target on shares of Kymera Therapeutics in a research report on Tuesday, January 21st.

Insider Activity at Kymera Therapeutics

In other Kymera Therapeutics news, CFO Bruce N. Jacobs sold 7,035 shares of the company’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total value of $214,215.75. Following the sale, the chief financial officer now directly owns 201,886 shares of the company’s stock, valued at approximately $6,147,428.70. This represents a 3.37 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Ellen Chiniara sold 2,241 shares of the business’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $30.45, for a total value of $68,238.45. Following the completion of the transaction, the insider now directly owns 80,085 shares of the company’s stock, valued at approximately $2,438,588.25. This trade represents a 2.72 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 10,659 shares of company stock worth $324,567 over the last quarter. Insiders own 15.82% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of KYMR. Walleye Capital LLC acquired a new stake in shares of Kymera Therapeutics during the 3rd quarter worth approximately $472,000. HighTower Advisors LLC purchased a new stake in Kymera Therapeutics during the third quarter worth $494,000. Wellington Management Group LLP grew its position in Kymera Therapeutics by 7.2% during the third quarter. Wellington Management Group LLP now owns 4,618,359 shares of the company’s stock valued at $218,587,000 after buying an additional 308,954 shares during the period. Franklin Resources Inc. increased its holdings in Kymera Therapeutics by 35.1% in the third quarter. Franklin Resources Inc. now owns 29,440 shares of the company’s stock valued at $1,356,000 after buying an additional 7,647 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its position in shares of Kymera Therapeutics by 212.6% in the third quarter. JPMorgan Chase & Co. now owns 140,491 shares of the company’s stock worth $6,649,000 after acquiring an additional 95,547 shares during the period.

Kymera Therapeutics Stock Performance

Shares of KYMR opened at $25.43 on Tuesday. The stock has a market capitalization of $1.65 billion, a PE ratio of -10.87 and a beta of 2.22. The company has a 50 day moving average price of $31.36 and a 200-day moving average price of $39.53. Kymera Therapeutics has a fifty-two week low of $19.45 and a fifty-two week high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR) last announced its earnings results on Thursday, February 27th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.12). The company had revenue of $7.39 million for the quarter, compared to the consensus estimate of $14.81 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. Equities research analysts forecast that Kymera Therapeutics will post -2.79 EPS for the current year.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.